SCHEDULE: TCG Crossover Discloses 6.4% Stake in LB Pharmaceuticals

TCG Crossover Fund II, L.P. and related entities have filed an amendment reporting a 6.4% beneficial ownership stake in LB Pharmaceuticals Inc.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu collectively report beneficial ownership of 1,839,489 shares of LB Pharmaceuticals Inc. common stock.
• This holding represents 6.4% of the total outstanding common stock of the issuer.
• The reporting persons maintain shared voting and dispositive power over the shares.
• The filing serves as an amendment to an original Schedule 13G filed on September 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing reflecting stable institutional ownership without indicating immediate strategic changes or market-moving events.

Positives

• Institutional investor maintains a significant 6.4% equity position, signaling continued interest in the company.

Negatives

• None identified in this regulatory disclosure.

Risks

• The reporting persons disclaim any intent to change or influence the control of the issuer, limiting the potential for activist-driven strategic shifts.

Future Outlook

The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for passive institutional investors. Maintaining a 6.4% stake suggests a long-term investment thesis in the pharmaceutical sector, consistent with the behavior of crossover funds that bridge private and public market investments.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for beneficial ownership reporting.
• The 6.4% stake is typical for institutional crossover funds holding positions in small-to-mid-cap biotech companies.

Stakeholder Impact

• Shareholders may view the continued 6.4% stake by TCG Crossover as a sign of institutional confidence in the company's long-term prospects.

Next Steps

• The reporting persons will continue to monitor their investment in LB Pharmaceuticals Inc.

Key Dates

Keywords

LB Pharmaceuticals, Schedule 13G, TCG Crossover, Beneficial Ownership, Institutional Investor, Equity Stake